Hyperbaric Oxygen Fibromyalgia Research: A Summary

What does research say about hyperbaric oxygen and fibromyalgia?

Fibromyalgia is one of the more actively studied topics in hyperbaric research. Prospective studies — including a frequently cited Israeli trial — have reported changes in pain measures and brain imaging after courses of hyperbaric sessions, while reviewers note small sample sizes and the difficulty of blinding participants.

Despite ongoing interest, fibromyalgia treatment guidelines do not include hyperbaric oxygen, and larger controlled trials are needed before conclusions can be drawn.

Research in this area is ongoing and results to date are preliminary. Published studies vary in size, pressure levels, and session protocols, and major health authorities have not approved hyperbaric oxygen therapy for this condition. This article summarizes the research topic for educational purposes only.

Why do families and individuals explore mild HBOT for fibromyalgia?

Interest in mild hyperbaric sessions among people affected by fibromyalgia generally centers on the same general wellness themes reported by other users of mHBOT — relaxation, routine, and structured recovery time in a controlled environment.

OxyEdge chambers are wellness products and are not intended to diagnose, treat, cure, or prevent any disease. Hyperbaric oxygen therapy is not FDA-cleared for this use. Anyone considering hyperbaric sessions in connection with a health condition should consult a licensed physician first.

What is mild hyperbaric oxygen therapy (mHBOT)?

Mild hyperbaric oxygen therapy involves sitting or reclining inside a sealed chamber pressurized above normal atmospheric pressure, generally between 1.3 and 2.0 ATA, while breathing supplemental oxygen from a concentrator. Sessions typically last 60 to 90 minutes.

Hard-shell chambers hold pressure precisely because their rigid walls do not flex. OxyEdge manufactures only hard-shell chambers and does not sell soft-shell inflatable units, which are more prone to leaks and pressure loss.

Clinic-grade equipment for home use: the OxyEdge approach

OxyEdge manufactures the same hard-shell mild hyperbaric chambers used by wellness clinics, now available for in-home use through the OxyEdge OS™ operating system. OxyEdge OS automates pressurization, session protocols, and real-time monitoring so a home user operates clinic-grade equipment with guided, repeatable sessions.

Every OxyEdge chamber is a rigid hard-shell vessel operating in the mild hyperbaric range up to 2.0 ATA, built in the USA with ISO 13485 / ISO 9001 compliant manufacturing, and backed by a Five-Year Limited Warranty with lifetime support.

Frequently Asked Questions

What did the most-cited fibromyalgia hyperbaric study find?

A prospective Israeli trial reported changes in symptoms and brain imaging in women with fibromyalgia after hyperbaric sessions. Researchers consider results preliminary due to study size and design limits.

Which OxyEdge chambers offer lying-down comfort?

The OxyEdge Revive and Elite+ feature reclining designs, and the Enclave Series offers premium seated comfort — all hard-shell, operating up to 2.0 ATA.

Is hyperbaric oxygen therapy approved to treat fibromyalgia?

No. Hyperbaric oxygen therapy is not FDA-cleared for fibromyalgia. Published research is exploratory, and OxyEdge chambers are wellness products that make no medical treatment claims. Consult a licensed physician about any health condition.

Is an OxyEdge home chamber the same as a clinic chamber?

OxyEdge builds the same hard-shell mild hyperbaric chambers used by wellness clinics, with the OxyEdge OS™ operating system adapting clinic-grade equipment for guided in-home use.